LEADER 06869nam 2201945z- 450 001 9910557623503321 005 20231214132838.0 035 $a(CKB)5400000000045180 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69075 035 $a(EXLCZ)995400000000045180 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aTargeting STAT3 and STAT5 in Cancer 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (578 p.) 311 $a3-03943-036-X 311 $a3-03943-037-8 330 $aEvery minute, 34 new patients are diagnosed with cancer globally. Although over the past 50 years treatments have improved and survival rates have increased dramatically for several types of cancers, many remain incurable. Several aggressive types of blood and solid cancers form when mutations occur in a critical cellular signaling pathway, the JAK-STAT pathway; (Janus Kinase-Signal Transducer and Activator of Transcription). Currently, there are no clinically available drugs that target the oncogenic STAT3/5 proteins in particular or their Gain of Function hyperactive mutant products. Here, we summarize targeting approaches on STAT3/5, as the field moves towards clinical applications as well as we illuminate on upstream or downstream JAK-STAT pathway interference with kinase inhibitors, heat shock protein blockers or changing nuclear import/export processes. We cover the design paradigms and medicinal chemistry approaches to illuminate progress and challenges in understanding the pleiotropic role of STAT3 and STAT5 in oncogenesis, the microenvironment, the immune system in particular, all culminating in a complex interplay towards cancer progression. 606 $aResearch & information: general$2bicssc 606 $aBiology, life sciences$2bicssc 610 $amultiple myeloma 610 $aSTAT3 610 $aS3I-1757 610 $ananoparticle 610 $aCD38 610 $asiRNA/RNAi 610 $apolyethylenimine 610 $aPEI 610 $alipopolyplex 610 $asiRNA delivery 610 $aglioma 610 $aglioblastoma 610 $aSTAT5 610 $aAKT 610 $aERK1/2 610 $aprolactin 610 $aandrogens 610 $aprostate cancer 610 $aknockout 610 $aescape mechanisms 610 $astem/progenitor cells 610 $acell hierarchy 610 $acancer 610 $aCD4+ T cells 610 $aCD8+ T cells 610 $amyeloid cells 610 $aimmune check point 610 $ahepatitis C virus (HCV) 610 $acirrhosis 610 $ahepatocellular carcinoma (HCC) 610 $aendoplasmic reticulum (ER) stress 610 $aoxidative stress (OS) 610 $aunfolded protein response (UPR) 610 $amicroRNA-122 (miR-122) 610 $anuclear factor erythroid 2-related factor 2 (NRF2) 610 $asignal transducer and activator of transcription 3 (STAT3) 610 $ahepatocyte nuclear factor 4 alpha (HNF4A) 610 $asolid cancers 610 $acell cycle 610 $aapoptosis 610 $ainflammation 610 $amitochondria 610 $astemness 610 $atumor suppression 610 $amelanoma 610 $aautoimmune disease 610 $aimmunotherapy 610 $atumor-immune cell interactions 610 $abreast cancer 610 $aPD-L1 610 $aM2 macrophages 610 $aNK cells 610 $aSTAT3 inhibitor XIII 610 $ahedging 610 $atransaction costs 610 $adynamic programming 610 $arisk management 610 $apost-decision state variable 610 $acancer progression 610 $acancer-stem cell 610 $acytokine 610 $atherapy resistance 610 $ametastasis 610 $aimmunosuppression 610 $atumor microenvironment 610 $aproliferation 610 $atyrosine kinase 2 610 $aJAK family of protein tyrosine kinases 610 $asignal transducer and activator of transcription 610 $acytokine receptor signaling 610 $again-of-function mutation 610 $atumorigenesis 610 $aADAM17 610 $ainterleukin-6 610 $atrans-signaling 610 $aepidermal growth factor receptor (EGF-R) 610 $ashedding 610 $ametalloprotease 610 $atumor necrosis factor alpha (TNF?) 610 $ainflammation associated cancer 610 $acolon cancer 610 $alung cancer 610 $aSH2 domain 610 $amutations 610 $aautosomal-dominant hyper IgE syndrome 610 $ainflammatory hepatocellular adenomas 610 $aT-cell large granular lymphocytic leukemia 610 $aT-cell prolymphocytic leukemia 610 $agrowth hormone insensitivity syndrome 610 $anuclear pore complex 610 $anuclear transport receptors 610 $anucleocytoplasmic shuttling 610 $atargeting 610 $atumor-associated macrophages 610 $aadoptive T cell therapy 610 $aimmune suppression 610 $aSTAT transcription factors 610 $aJAK 610 $aSTAT 610 $aT-PLL 610 $aT-cell leukemia 610 $ameta-analysis 610 $aSTAT5B signaling 610 $asmall-molecule inhibitors 610 $acancer models 610 $acompanion animals 610 $acomparative oncology 610 $apharmacological inhibitor 610 $aSTAT5 signaling 610 $achemotherapy resistance 610 $amyeloid leukemia 610 $aheat shock proteins 610 $achaperones 610 $astabilization 610 $atargeted therapy 610 $aovarian cancer 610 $ahematopoietic cancers 610 $atherapeutic targeting 610 $apharmacological inhibitors 610 $amTOR 610 $aBone Marrow Failure Syndromes 610 $alymphocytes 610 $alymphoma 610 $aT-cells 610 $aRHOA 610 $aNGS 610 $aMPN 610 $aJAK2 V617F 610 $aneoplastic stem cells 615 7$aResearch & information: general 615 7$aBiology, life sciences 700 $aMoriggl$b Richard$4edt$01287874 702 $aGunning$b Patrick$4edt 702 $aKeseru?$b Gyo?rgy Miklo?s$4edt 702 $aMoriggl$b Richard$4oth 702 $aGunning$b Patrick$4oth 702 $aKeseru?$b Gyo?rgy Miklo?s$4oth 906 $aBOOK 912 $a9910557623503321 996 $aTargeting STAT3 and STAT5 in Cancer$93020509 997 $aUNINA